zolbetuximab
astellas
[]
announced today at #gi23: data from our phase 3 trial in claudin 18.2-positive, her2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38